LifeSci Capital analyst maintained a Buy rating on Soleno Therapeutics today and set a price target of $120.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LifeScience Cap’s rating is based on several compelling factors that highlight the potential of Soleno Therapeutics. The recent FDA approval of Vykat XR for treating hyperphagia in Prader Willi syndrome has shown promising early launch metrics, with significant uptake among patients and healthcare providers. The product has achieved substantial market access, covering approximately one-third of lives in the U.S., and is expected to grow as the product profile becomes more familiar and reimbursement processes improve.
Despite the competitive landscape with upcoming readouts from other PWS programs, LifeScience Cap believes that Vykat XR is well-positioned for success due to its unique product profile and the high unmet need in the market. The planned expansion into the European market in 2026 is anticipated to nearly double the addressable market, with estimated peak sales reaching $2.1 billion. The valuation, supported by a DCF model, reflects these growth prospects and assigns a high probability of success for Vykat XR in both the U.S. and EU markets.
In another report released on September 8, TD Cowen also maintained a Buy rating on the stock with a $120.00 price target.